Chemitope Glycopeptide

Chemitope Glycopeptide is a private, pre-clinical stage biotech founded in 2016, focusing on the synthesis of complex glycopeptides. Its core technology enables atomic-level control for producing homogeneous glycopeptides at scale, supporting both internal vaccine programs and external partners in academia and pharma. The company is led by CEO Baptiste Aussedat, an expert in glycopeptide chemistry, and its work is validated by high-profile publications and the production of materials for a Phase I clinical trial.

Proprietary chemical synthesis platform for homogeneous glycopeptides, featuring convergent assembly of modularly synthesized N-linked glycans with peptides. Enables atomic-level structural control, scalability to gram quantities, and incorporation of diverse post-translational modifications.

Competition includes academic labs and a small number of specialized CROs in carbohydrate chemistry. For therapeutic immunogens, competition is with large vaccine developers and biotechs using other platforms (mRNA, viral vectors). Chemitope's differentiation lies in its pure chemical synthesis approach enabling unparalleled structural precision and homogeneity.